ArticleAmerican journal of hematology2019
Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
Article in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06019208 (Genomics and Personalized Medicine for All Though Artificial Intelligence in Haematological Diseases), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genomics and Personalized Medicine for All Though Artificial Intelligence in Haematological Diseases
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.Blood advances · 2024Trial
- One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.Blood advances · 2023Trial
- Cryopreservation of Red Blood Cells From Sickle Cell Disease Patients for Comparison of Oxygen Gradient Ektacytometry Parameters Between Laboratories to Enable Data Harmonization.International journal of laboratory hematology · 2026Article
- Red blood cell deformability as a mechanobiological marker of CFTR dysfunction in cystic fibrosis.iScience · 2026Article
- Cure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials.Blood advances · 2026Article
- Article
- Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial.Nature cancer · 2026Article
- Clinical, humanistic, and economic burden of sickle cell disease in The Jazan Region, Saudi Arabia.PloS one · 2026Observational
- A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies.Blood advances · 2025Article
- Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy.Science advances · 2025Article
- The role of red blood cell characteristics and viscosity in sickle cell retinopathy and maculopathy.British journal of haematology · 2025Article
- Article
- A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease.EJHaem · 2024Article
- Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease.Blood advances · 2024Article
- Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment.Haematologica · 2023Article
- Classification of red cell dynamics with convolutional and recurrent neural networks: a sickle cell disease case study.Scientific reports · 2023Article
- The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.Blood · 2022Article
- Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Comment on: Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia.British journal of haematology · 2022Article
- Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia.British journal of haematology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
In sickle cell disease (SCD), sickle hemoglobin (HbS) polymerizes upon deoxygenation, resulting in sickling of red blood cells (RBCs). These sickled RBCs have strongly reduced deformability, leading to vaso-occlusive crises and chronic hemolytic anemia. To date, there are no reliable laboratory parameters or assays capable of predicting disease severity or monitoring treatment effects. We here report on the oxygenscan, a newly developed method to measure RBC deformability (expressed as Elongation Index - EI) as a function of pO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.